Phuturdex › Diseases › Muscular disease
Drugs in development · updated 30 October 2026
Muscular disease: drugs in development
As of 30 October 2026 there are 12 active clinical trials (recruiting or ongoing, phases I–III) on 12 drugs for muscular disease. 9 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Andecaliximab | II–III | 1 | NCT06508021 |
| AOC 1044 | III | 1 | NCT07587242 |
| Deramiocel | III | 1 | NCT05126758 |
| Encaleret | III | 1 | NCT05680818 |
| VX-670 | I–II | 2 | NCT06185764 |
| NapazimoneKL1333 | II | 1 | NCT05650229 |
| TributyrinGlycerol Tributyrate | I–II | 1 | NCT06792500 |
| AZD5492 | I | 1 | NCT06916806 |
| XmAb657 | I | 1 | NCT07284797 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Onasemnogene abeparvovecZolgensma®, Itvisma® | III | 1 | NCT05335876 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 1 | NCT06626919 |
| FludarabineFludara, FLUDARABIN | I | 1 | NCT06626919 |
Sorted by most advanced phase and number of active trials.
All 12 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Duchenne muscular dystrophy 35 drugs
- Myositis 42 drugs
- Systemic scleroderma 77 drugs
- Systemic lupus erythematosus 178 drugs
- Dermatomyositis 52 drugs
- Rheumatoid arthritis 130 drugs
- Autoimmune disease 94 drugs
- Lupus nephritis 64 drugs
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 35 drugs
- Myotonic dystrophy 10 drugs
- Polymyositis 36 drugs
- Spasticity 10 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Neuromuscular disease 14 drugs
- Neurologic Manifestations 15 drugs
- Musculoskeletal disorder 22 drugs
- Neuromuscular manifestations 5 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009135 “Muscular Diseases”.